These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 9856143)

  • 1. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
    Oriana S; Coradini D; Sasso GM; Di Fronzo G
    Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
    Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N
    Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment.
    Søreide JA; Lea OA; Varhaug JE; Skarstein A; Kvinnsland S
    Eur J Surg Oncol; 1992 Apr; 18(2):112-8. PubMed ID: 1582503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.